The 80.5 Percent Headline, and the Three Confirmed Responses Behind It

Vividion Therapeutics had one number it wanted at the top of the page, and on September 29 it put it there: 80.5 percent. That is the disease-control rate Vividion reported for its lead cancer drug, VVD-214, in patients with microsatellite-instable colorectal cancer, published the same day in Nature Medicine. Disease control is a generous way to keep score, though. Count only the colorectal tumors that actually shrank to the response threshold and you get three.

The idea under the drug is a clever one. VVD-214 shuts down the Werner syndrome helicase, WRN, and only where that shutdown turns lethal. Cancers with microsatellite instability, the ones driven by broken mismatch-repair machinery, pile up long expanded stretches of repeated DNA that fold into knots the cell cannot unwind without WRN. Take WRN away and the tumor’s own genome, already loaded with these fragile repeats, tears apart in double-strand breaks, while cells with intact repair and none of the expanded repeats are largely spared. That synthetic-lethal vulnerability was worked out in 2019, and WRN has been one of oncology’s most-chased targets ever since, with Novartis and others running at the same finish line.

The patients in this trial had run out of gentler options. The study enrolled 88 for safety and could measure a response in 66. Their median count of prior therapies was three, and 95.5 percent had already been through an immune checkpoint inhibitor, the Keytruda class that is supposed to be the standard move for microsatellite-instable tumors precisely because those tumors are so visible to the immune system. This was a cohort for whom the standard move had already failed, which is what makes even a modest signal worth reading, and what makes the headline number slippery.

Here is the arithmetic the release does not foreground. Disease-control rate counts every patient whose tumor shrank or merely held steady for a defined window, which makes it a roomy bucket by design. Across all 66 evaluable patients it came to 74.2 percent, and in the colorectal subset it was the advertised 80.5 percent. Confirmed partial responses, tumors that actually shrank by the standard RECIST threshold, were a different matter: seven of the 66 overall, or 10.6 percent, and in the colorectal group just 7.3 percent, which works out to three patients.

The gap is not fraud; it is framing. “Stable disease” in someone on a fourth line of treatment can mean the drug is doing quiet work, or it can mean the cancer was going to sit still for a few months on its own. A single-arm phase 1 with no control arm cannot tell you which, and this trial has none. What it can report is what happened to the people who took the drug: a median progression-free survival of 6.7 months overall and 7.3 months in colorectal, a median overall survival of 17.6 months across the 66, and a 12-month survival estimate of 78.3 percent in colorectal, where median overall survival was not yet reached. All three colorectal responders were still in response when the data were cut.

The safety sheet is less pristine than the release suggests. Most drug-related effects were grade 1 or 2 nausea, vomiting and diarrhea. But grade 3 or 4 treatment-related events, Nature Medicine reports, reached 15.9 percent of patients, roughly one in six, and while only 2.3 percent stopped for a treatment-related effect and 3.4 percent counting every adverse event, that is not the spotless profile “well tolerated” tends to conjure. The compound clears fast, a half-life of about 4.4 hours reported at last year’s AACR meeting.

It is worth being clear about who owns this. Vividion, a San Diego company, discovered VVD-214, which also carries the designation RO7589831, and developed it under a 2020 collaboration with Roche, then took the global rights back from the Swiss company in June 2025. Vividion itself is a wholly owned subsidiary of Bayer, the German pharmaceutical giant, which paid about $1.5 billion up front to buy it in 2021. Roche was the original sponsor of record on the trial; Vividion is now. American science, in other words, with the upside pooling in Leverkusen and, for a while, Basel. That is not a knock on the data. It is a reason to watch how a single-arm phase 1 signal gets narrated to American patients, and to notice who collects on the valuation if it gets narrated as a breakthrough.

Then there is the catch no release leads with. The same runaway mutation rate that makes these tumors vulnerable is exactly what lets them mutate around the drug. In laboratory work on WRN inhibitors published this year, microsatellite-instable cancer cells picked up on-target resistance mutations within two to four weeks of exposure, and xenograft tumors regrew about three weeks after treatment stopped. That work tested Novartis’s HRO761 and two experimental tool compounds rather than VVD-214, so it is a warning about the whole class, not a verdict on this one drug, and a preclinical one at that, not a patient failure anyone has clocked. But a hypermutable cancer is a moving target by definition, and durability, the very property those three responders showed, is the one most at risk over time. Vividion seems to know it. Its next two studies, both named in Vividion’s announcement, do not test the drug alone at all: one pairs VVD-214 with bevacizumab, the other with pembrolizumab. The monotherapy story is being folded into combinations before the monotherapy story is finished.

None of this makes VVD-214 a failure. In a disease where the standard immunotherapy has already quit, a tolerable pill that produced a handful of durable responses is a result worth having, and the mechanism under it is one of the prettier ideas to reach a clinic in years. It just is not the result the headline sold. Vividion put 80.5 percent at the top of the page and the confirmed-response rate farther down, in the body of the document, where the careful readers live. Both numbers are in the paper. The company knew which one photographs better.

Sources

1. Nature Medicine, “Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial” (Yap et al.), 29 Sept 2026
2. Vividion Therapeutics, clinical-data announcement for VVD-214, 29 Sept 2026
3. FierceBiotech, Bayer’s Vividion secures rights to the only clinical-stage covalent WRN inhibitor from partner Roche
4. Nature (2019), WRN helicase is a synthetic lethal target in microsatellite-unstable cancers (Chan et al.)
5. Molecular Cancer Therapeutics, MSI cancer cells acquire on-target resistance mutations to WRN helicase inhibitors (2026)
6. Nature (2024), Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers (Novartis)
7. ecancer, WRN inhibitor RO7589831 in MSI/dMMR advanced solid tumours (AACR 2025 presentation)